30 Sep 2025
Take a deeper dive into interpreting clinical drug testing results. Part two in this webinar series focuses on several patient case studies, highlighting common and complex scenarios that providers may encounter in medication-assisted treatment (MAT) programs. Addiction medicine specialist Dr. Tania Hernandez joined our panel to offer clinical insights and practical guidance from a provider’s perspective.
What will I learn about MAT in Part 2 of this webinar?
In Part 2, our toxicology experts, including an addiction medicine provider, cover:
- How to interpret clinical drug testing results using real-world patient case studies
- Supporting compliance and identifying discrepancies between self-reports and lab results
- Emerging trends including the use of alpha-2 agonists like xylazine and medetomidine in illicit drug supplies
Speakers:
Hemamalini Ketha, PhD, NRCC, SC (ASCP), FAAC
Discipline Director, Clinical Toxicology, Labcorp
Karla J. Walker, PharmD, DABCC, FAACC
Discipline Director, Clinical Toxicology, Labcorp
Dr. Tania Hernandez
Dr. Hernandez is a board-certified physician in family medicine and addiction medicine. Dr. Hernandez has led the development of comprehensive addiction treatment programs across diverse clinical settings, including community health centers and correctional facilities treating high-risk and underserved populations. She currently directs the MOUD program at the Monroe Correctional Complex in Washington State, integrating primary care, behavioral health and harm reduction into recovery pathways.